Detalles de la búsqueda
1.
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.
Diabetes Obes Metab
; 23(8): 1961-1967, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33908683
2.
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
Diabetes Obes Metab
; 21(11): 2564-2569, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31364269
3.
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Diabetes Obes Metab
; 20(11): 2532-2540, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29888547
4.
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol
; 7(6): 429-441, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30992195
Resultados
1 -
4
de 4
1
Próxima >
>>